Using insights from Ipsos’ India Oncology Monitor and India Oncology Sales Monitor, together with secondary desk research, this report provides an exhaustive analysis of the Indian oncology landscape, and the environment to consider to ensure pharma brand and company success in this region.
The wild-type (WT) stage III-IV non-small cell lung cancer (NSCLC) indication presents a key opportunity for treatment innovation. Using real-world clinical insights from Ipsos’ Oncology Monitor, this report provides an invaluable viewpoint for those operating in or entering this dynamic space.
Leveraging insights from Ipsos’ Global Oncology Monitor, these reports provide a granular view of individual tumour treatment landscapes. With key metrics including trended market shares, treatment algorithms, patient and physician profiling – and more – they provide the perfect overview for companies looking to establish, maintain or expand their presence in specific tumour indications.
The key facts about oncology drug products available in the US, EU4 & UK ‑ all in one interactive interface. This intuitive Tableau-based platform allows you instant access to metrics relevant to your product and your competitors’ products, including brand/molecule name, indication details, approval dates, and more.
Leveraging insights from Ipsos’ Global Oncology Monitor, these reports provide a granular view of oncology biomarker landscapes, their complexities, and their evolution. Align your portfolio with the latest advancements in biomarker-driven therapies to address unmet patient needs – all in the regions where you need visibility.
Market sizing is a crucial exercise to understand the potential reach and value of a drug or treatment. Based on extrapolations of both Ipsos real-world and secondary data, access validated universe sizes across a range of tumour types. Size customer workloads, their management of multiple indications, and annual drug-treated prevalence figures.
Against a comprehensive backdrop of the lung cancer treatment landscape, explore prescriber expectations of the impact of subcutaneous versions of immunotherapies (IOs) in this field. Understand what will drive and hinder adoption – and the potential change in usage of different treatments as a result.